FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136536416> ?p ?o ?g. }

• W3136536416 endingPage "1105" @default.
• W3136536416 startingPage "1096" @default.
• W3136536416 abstract "PERJETA (pertuzumab), administered with Herceptin (trastuzumab), is used in the treatment of human epidermal growth factor receptor 2-positive breast cancer. Pertuzumab is currently approved with an initial loading dose of 840 mg, followed by a 420-mg maintenance dose intravenously every 3 weeks. A reloading dose is required if there is a ≥6-week delay in treatment. In response to the potential treatment disruption due to COVID-19, the impact of dose delays and alternative dosing regimens on intravenous pertuzumab for human epidermal growth factor receptor 2-positive breast cancer treatment is presented. Simulations were conducted by using the validated population pharmacokinetic model for pertuzumab, and included (1) 4-, 6-, and 9-week dose delays of the 840 mg/420 mg every 3 weeks dosing regimen and (2) 840 mg/420 mg every 4 weeks and 840 mg every 6 weeks alternative dosing regimens. Simulations were compared with the currently approved pertuzumab dosing regimen. The simulations in 1000 virtual patients showed that a dose reload (840 mg) is required following a dose delay of ≥6 weeks to maintain comparable Ctrough (lowest concentration before the next dose is given) levels to clinical trials. The 840 mg/420 mg every 4 weeks and 840 mg every 6 weeks alternative dosing regimens decrease median steady-state Ctrough by ≈40% compared with the approved regimen, and <90% of patients will be above the target Ctrough . Thus, the alternative 840 mg/420 mg every 4 weeks and 840 mg every 6 weeks pertuzumab dosing regimens are not recommended. Flexibility for intravenous PERJETA-based regimens is available with an alternative route of pertuzumab administration (subcutaneous vs intravenous)." @default.
• W3136536416 created "2021-03-29" @default.
• W3136536416 creator A5048086631 @default.
• W3136536416 creator A5049025588 @default.
• W3136536416 creator A5065578593 @default.
• W3136536416 creator A5068222768 @default.
• W3136536416 creator A5071673618 @default.
• W3136536416 creator A5072923250 @default.
• W3136536416 creator A5083418555 @default.
• W3136536416 creator A5085929266 @default.
• W3136536416 creator A5086259587 @default.
• W3136536416 creator A5086463590 @default.
• W3136536416 date "2021-07-07" @default.
• W3136536416 modified "2023-09-27" @default.
• W3136536416 title "Impact of Dose Delays and Alternative Dosing Regimens on Pertuzumab Pharmacokinetics" @default.
• W3136536416 cites W2018147385 @default.
• W3136536416 cites W2101979288 @default.
• W3136536416 cites W2122983196 @default.
• W3136536416 cites W2123591186 @default.
• W3136536416 cites W2137228442 @default.
• W3136536416 cites W2151425644 @default.
• W3136536416 cites W2166199281 @default.
• W3136536416 cites W2318066535 @default.
• W3136536416 cites W2379981061 @default.
• W3136536416 cites W2532646138 @default.
• W3136536416 cites W2571451272 @default.
• W3136536416 cites W2624590002 @default.
• W3136536416 cites W2901818724 @default.
• W3136536416 cites W2905700230 @default.
• W3136536416 cites W2937862941 @default.
• W3136536416 cites W3027069565 @default.
• W3136536416 cites W3117303512 @default.
• W3136536416 doi "https://doi.org/10.1002/jcph.1855" @default.
• W3136536416 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8361934" @default.
• W3136536416 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33719071" @default.
• W3136536416 hasPublicationYear "2021" @default.
• W3136536416 type Work @default.
• W3136536416 sameAs 3136536416 @default.
• W3136536416 citedByCount "1" @default.
• W3136536416 countsByYear W31365364162022 @default.
• W3136536416 crossrefType "journal-article" @default.
• W3136536416 hasAuthorship W3136536416A5048086631 @default.
• W3136536416 hasAuthorship W3136536416A5049025588 @default.
• W3136536416 hasAuthorship W3136536416A5065578593 @default.
• W3136536416 hasAuthorship W3136536416A5068222768 @default.
• W3136536416 hasAuthorship W3136536416A5071673618 @default.
• W3136536416 hasAuthorship W3136536416A5072923250 @default.
• W3136536416 hasAuthorship W3136536416A5083418555 @default.
• W3136536416 hasAuthorship W3136536416A5085929266 @default.
• W3136536416 hasAuthorship W3136536416A5086259587 @default.
• W3136536416 hasAuthorship W3136536416A5086463590 @default.
• W3136536416 hasBestOaLocation W31365364162 @default.
• W3136536416 hasConcept C112705442 @default.
• W3136536416 hasConcept C121608353 @default.
• W3136536416 hasConcept C126322002 @default.
• W3136536416 hasConcept C22979827 @default.
• W3136536416 hasConcept C2777288759 @default.
• W3136536416 hasConcept C2779786085 @default.
• W3136536416 hasConcept C2781164504 @default.
• W3136536416 hasConcept C2781413609 @default.
• W3136536416 hasConcept C2908647359 @default.
• W3136536416 hasConcept C35294091 @default.
• W3136536416 hasConcept C530470458 @default.
• W3136536416 hasConcept C71924100 @default.
• W3136536416 hasConcept C98274493 @default.
• W3136536416 hasConcept C99454951 @default.
• W3136536416 hasConceptScore W3136536416C112705442 @default.
• W3136536416 hasConceptScore W3136536416C121608353 @default.
• W3136536416 hasConceptScore W3136536416C126322002 @default.
• W3136536416 hasConceptScore W3136536416C22979827 @default.
• W3136536416 hasConceptScore W3136536416C2777288759 @default.
• W3136536416 hasConceptScore W3136536416C2779786085 @default.
• W3136536416 hasConceptScore W3136536416C2781164504 @default.
• W3136536416 hasConceptScore W3136536416C2781413609 @default.
• W3136536416 hasConceptScore W3136536416C2908647359 @default.
• W3136536416 hasConceptScore W3136536416C35294091 @default.
• W3136536416 hasConceptScore W3136536416C530470458 @default.
• W3136536416 hasConceptScore W3136536416C71924100 @default.
• W3136536416 hasConceptScore W3136536416C98274493 @default.
• W3136536416 hasConceptScore W3136536416C99454951 @default.
• W3136536416 hasIssue "8" @default.
• W3136536416 hasLocation W31365364161 @default.
• W3136536416 hasLocation W31365364162 @default.
• W3136536416 hasLocation W31365364163 @default.
• W3136536416 hasOpenAccess W3136536416 @default.
• W3136536416 hasPrimaryLocation W31365364161 @default.
• W3136536416 hasRelatedWork W2064759457 @default.
• W3136536416 hasRelatedWork W2370929226 @default.
• W3136536416 hasRelatedWork W2379280247 @default.
• W3136536416 hasRelatedWork W2766550598 @default.
• W3136536416 hasRelatedWork W2942467058 @default.
• W3136536416 hasRelatedWork W2945264506 @default.
• W3136536416 hasRelatedWork W2972558787 @default.
• W3136536416 hasRelatedWork W3018168093 @default.
• W3136536416 hasRelatedWork W3122926187 @default.
• W3136536416 hasRelatedWork W3151787567 @default.
• W3136536416 hasVolume "61" @default.
• W3136536416 isParatext "false" @default.

• next